Abstract:Purpose of reviewThis article reviews current treatment options and strategies and provides an update on the status of drug development programs of new therapeutic agents for inflammatory bowel diseases (IBD).Recent findingsIn the past two decades, tumor necrosis factor antagonist therapy has given clinicians better treatment options. However, not all patients respond to induction therapy with these agents, and of those initially responding, up to 40% ultimately lose response due to suboptimal drug exposure (e.g., caused by immunogenicity), side effects, or other poorly characterized mechanisms. Recently, additional therapies, such as vedolizumab, an integrin blocker that prevents T cell trafficking to the gut, and ustekinumab, an antibody blocking the common p40 subunit of interleukin (IL)-12 and 23, were introduced to the market. In addition, other agents including novel anti-trafficking therapies (e.g., anti-β7 and sphingosine-1-phosphate receptor modulators), antibodies against p19 (unique to IL-23), and small molecules including Janus kinase inhibitors are under investigation in phase II and III trials.Furthermore, the management of IBD has evolved from targeting control of symptoms to suppression of mucosal inflammation. This shift in thinking has been accompanied by the early use of highly effective therapy in poor prognosis patients, accelerated treatment escalation and utilization of a treat to target paradigm approach, and adoption of therapeutic drug monitoring.SummaryThe treatment landscape for IBD is rapidly evolving with the recent approval of novel biologics as well as several other agents in late phase of clinical development. Moreover, we have started to use agents more intelligently with a focus on risk stratification and early use of highly effective therapy in high-risk patients, treat to target using patient-reported outcomes (PROs), biomarkers, endoscopy, and therapeutic drug monitoring.

IBD in women of reproductive age: where do novel therapies fit in?

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions

Immunotherapy in inflammatory bowel disease: Novel and emerging treatments

Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review

Novel Therapies for Inflammatory Bowel Disease

A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy

Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs

The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape

Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease

Novel Targeted Therapies for Inflammatory Bowel Disease

Inflammatory Bowel Disease and Reproductive Health: A Focus on Pregnancy Planning and Outcomes

Inflammatory bowel disease in pregnancy and breastfeeding

Current and emerging therapeutic targets for IBD

Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease

Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents

Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems